Our study offers novel insights into targeting Arp2/3 complex subunits as an anti-cancer strategy and underscores the potential of ARPC1A as a novel biomarker for tumor diagnosis, prognosis, and the prediction of immune therapy responses. The gene discussed is ARPC1A; the disease is cancer.